Activities of doripenem (S-4661) against drug-resistant clinical pathogens.
Doripenem (formerly S-4661), a new 1-beta-methyl carbapenem, was challenged with a worldwide collection of 394 drug-refractory isolates. For endemic extended-spectrum beta-lactamase- and stably derepressed AmpC-producing enteric bacilli, the doripenem MICs at which 90% of the isolates were inhibited (MIC90s) were 0.03 to 0.5 microg/ml, generally lower than those of comparator carbapenems. A greater proportion of strains among carbapenem-resistant nonfermentative gram-negative bacilli were inhibited by doripenem at < or =4 microg/ml, and doripenem was the most active carbapenem (MIC90, 1 to 4 microg/ml) against penicillin-resistant streptococci.
The JONES Group/JMI Laboratories, Inc., North Liberty, Iowa 52317, USA. ronald-jones@jmilabs.com
Ronald N
RN
Jones
Holly K
HK
Huynh
Douglas J
DJ
Biedenbach
D001419:Bacteria / Q000187:drug effects* / Q000235:genetics; D001424:Bacterial Infections / Q000382:microbiology*; D015780:Carbapenems / Q000494:pharmacology*; D000077726:Doripenem; D024881:Drug Resistance, Bacterial; D005838:Genotype; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006801:Humans; D010641:Phenotype
D015780:Carbapenems; D000077726:Doripenem